Solasia Pharma KK (JP:4597) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Solasia Pharma K.K. reports significant year-on-year revenue decline in the first six months of 2024, with a decrease in profit and basic earnings per share. The company maintains a stable equity ratio, while its forward-looking revenue and profit forecasts suggest a potential rebound by the end of the fiscal year. No dividends were paid or forecasted for the fiscal year, reflecting the company’s cautious financial management amid its current performance.
For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.